UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany

Arthritis research & therapy, 2020-04, Vol.22 (1), p.81-81, Article 81

2020

Volltextzugriff (PDF)

Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry

Rheumatology (Oxford, England), 2020-09, Vol.59 (9), p.2287-2298

2020

Volltextzugriff (PDF)

Outcome of adult patients with JIA treated with the biosimilar Benepali ® : results of the biologic register JuMBO

Arthritis research & therapy, 2022-12, Vol.24 (1), p.271-271, Article 271

2022

Volltextzugriff (PDF)

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Arthritis research & therapy, 2019-05, Vol.21 (1), p.125-125, Article 125

2019

Volltextzugriff (PDF)

Safety of biologic therapies for the treatment of juvenile idiopathic arthritis

Expert opinion on drug safety, 2015-07, Vol.14 (7), p.1111-1126

Horneff, Gerd

2015

Volltextzugriff (PDF)

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

Pediatric rheumatology online journal, 2017-12, Vol.15 (1), p.86-86, Article 86

2017

Volltextzugriff (PDF)

Fluorescence optical imaging and musculoskeletal ultrasonography in juvenile idiopathic polyarticular disease before and during antirheumatic treatment - a multicenter non-interventional diagnostic evaluation

Arthritis research & therapy, 2017-06, Vol.19 (1), p.147-147, Article 147

2017

Volltextzugriff (PDF)

New drugs for treatment of juvenile idiopathic arthritis

Zeitschrift für Rheumatologie, 2019-09, Vol.78 (7), p.587

Horneff, Gerd

2019

Volltextzugriff (PDF)

Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score

Rheumatology (Oxford, England), 2014-07, Vol.53 (7), p.1229-1234

2014

Volltextzugriff (PDF)

Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis

Journal of rheumatology, 2005-09, Vol.32 (9), p.1832

2005

Volltextzugriff (PDF)

Treatment of non-systemic juvenile idiopathic arthritis

Nature reviews. Rheumatology, 2024-03, Vol.20 (3), p.170-181

2024

Volltextzugriff (PDF)

Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis

Rheumatology (Oxford, England), 2014-07, Vol.53 (7), p.1245-1249

2014

Volltextzugriff (PDF)

Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis

Rheumatology (Oxford, England), 2011-01, Vol.50 (1), p.214-221

2011

Volltextzugriff (PDF)

Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry

Arthritis & rheumatology (Hoboken, N.J.), 2014-09, Vol.66 (9), p.2580-2589

2014

Volltextzugriff (PDF)

Time of Disease‐Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug‐Free Remission in Young Adulthood

Arthritis care & research (2010), 2019-04, Vol.71 (4), p.471-481

2019

Volltextzugriff (PDF)

Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000–2013

Arthritis & rheumatology (Hoboken, N.J.), 2016-12, Vol.68 (12), p.3023-3034

2016

Volltextzugriff (PDF)

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

Arthritis research & therapy, 2016-11, Vol.18 (1), p.272, Article 272

2016

Volltextzugriff (PDF)

Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO

Rheumatology (Oxford, England), 2012-08, Vol.51 (8), p.1407-1415

2012

Volltextzugriff (PDF)

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis‐Related Arthritis

Arthritis care & research (2010), 2015-11, Vol.67 (11), p.1503-1512

2015

Volltextzugriff (PDF)

Efficacy and Safety of Etanercept in Patients With the Enthesitis‐Related Arthritis Category of Juvenile Idiopathic Arthritis: Results From a Phase III Randomized, Double‐Blind Study

Arthritis & rheumatology (Hoboken, N.J.), 2015-08, Vol.67 (8), p.2240-2249

2015

Volltextzugriff (PDF)

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Annals of the rheumatic diseases, 2018-12, Vol.77 (12), p.1710-1719

2018

Volltextzugriff (PDF)

Improvement in Health‐Related Quality of Life for Children With Juvenile Idiopathic Arthritis After Start of Treatment With Etanercept

Arthritis care & research (2010), 2014-02, Vol.66 (2), p.253-262

2014

Volltextzugriff (PDF)

Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis

Rheumatology (Oxford, England), 2024-01, Vol.63 (1), p.140-148

2024

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Aktive Filter

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(51)

Sprache

Englisch
(50)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(51)
Science & Technology
(51)
Humans
(50)
Rheumatology
(49)
Arthritis, Juvenile - Drug Therapy
(44)
Child
(42)
Female
(39)
Male
(39)
Adolescent
(36)
Antirheumatic Agents - Therapeutic Use
(35)
Child, Preschool
(25)
Juvenile Idiopathic Arthritis
(24)
Etanercept
(20)
Arthritis
(16)
Registries
(14)
Severity Of Illness Index
(13)
Antirheumatic Agents - Adverse Effects
(12)
Immunoglobulin G - Therapeutic Use
(12)
Methotrexate
(12)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany

Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry

Outcome of adult patients with JIA treated with the biosimilar Benepali ® : results of the biologic register JuMBO

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Safety of biologic therapies for the treatment of juvenile idiopathic arthritis

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

Fluorescence optical imaging and musculoskeletal ultrasonography in juvenile idiopathic polyarticular disease before and during antirheumatic treatment - a multicenter non-interventional diagnostic evaluation

New drugs for treatment of juvenile idiopathic arthritis

Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score

Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis

Treatment of non-systemic juvenile idiopathic arthritis

Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis

Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis

Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry

Time of Disease‐Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug‐Free Remission in Young Adulthood

Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000–2013

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO

Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis‐Related Arthritis

Efficacy and Safety of Etanercept in Patients With the Enthesitis‐Related Arthritis Category of Juvenile Idiopathic Arthritis: Results From a Phase III Randomized, Double‐Blind Study

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Improvement in Health‐Related Quality of Life for Children With Juvenile Idiopathic Arthritis After Start of Treatment With Etanercept

Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study

Aktive Filter

Suchergebnisse filtern